LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global factor VIII deficiency treatment market is projected to grow to USD 11 billion, at a CAGR of close to 6% ...

New York, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Hemophilia A (Factor VIII Deficiency) Clinical Trial Analysis by Trial Phase, Trial Status, Trial ...

The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...

DUBLIN--(BUSINESS WIRE)--The "Hemophilia a (Factor Viii Deficiency) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. The report enhances the ...

Dublin, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The "Hemophilia A (Factor VIII Deficiency) - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This ...

This page lists all known medications that could potentially lead to 'Factor VIII deficiency' as a side effect. It's important to note that mild side effects are quite common with medications. The ...

Research and Markets has announced the addition of the "Global Factor VIII Deficiency Treatment Market 2017-2021" report to their offering. The report forecasts the global factor VIII market to grow ...

VON Willebrand's disease is manifested by a deficiency of factor VIII (antihemophilic factor) and a prolonged bleeding time and is inherited as an autosomal dominant trait of variable penetrance. 1 ...

New York, May 02, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Hemophilia A (Factor VIII Deficiency) Clinical Trial Analysis by Trial Phase, Trial Status, Trial ...